We developed a chicken mucosa-targeting polymeric nanoparticle vaccine (~90 nm) co-delivering viral antigenCpG adjuvant using a water-in-oil-in-water double emulsion technique. The particles are biodegradablebiocompatible. This nanoparticle significantly stimulated chicken Harderian gland B cell proliferationsubsequent local IgAIgG secretion in tears. The mucosal Ig protected chickens from virus infection by lowering virus replication at the infection sitethereafter reducing tracheal epithelial ciliostasissystemic infection, relieving clinical symptoms.

As we continue to face the rapid increase in confirmed Coronavirus cases around the world, we created an AI-based pneumonia detection platform for COVID-19. The system is able to automatically detect high-risk patients with pneumonia that will then send information to doctors. With that information, the doctors are then able to make follow-up decisions and provide a treatment plan after the diagnosis. In specific, doctors from the Department of Medical Imaging provided us thousands of positive and negative chest x-rays for pneumonia as a training set. Our system has already been tested with and adopted by doctors at the NCKU Hospital. The system achieved 95% accuracy to detect the pneumonia symptom, based on 1400 test images.

Due to the recent outbreak of COVID-19ongoing mutants, we developed a coronavirus variant protein microarray that includes all the current spike mutationsthe wild-type viral antigensapplied in detecting immune responsesdrug specificities. We filed the patientspublished our findings in the Analytical Chemistry. Besides massive production of the coronavirus protein microarray, we also collaborated with a scanner company, developed artificial intelligence software,collaborated with suppliers. We are welcome any sort of collaboration.

BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19 as a first-in-class drug. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Related US and Taiwan patents have been granted.​ Therefore it is also applicable to fight against severe evolving coronaviruses in the future.

"We present here a portable device with isothermally mediated loop amplification (LAMP) for the diagnosis of infectious diseases. The main components included (1) roller conveyor, (2) hotplate,(3) temperaturemotion control panels. After mixing all the solutions by rollingsqueezing the sealed compartments, the LAMP strip was heated for 30 min for amplification. Finally, fluorescence results can be read with the naked eyeon a smartphone under the UV lamp. The 700g device is powered by a portable charger, making it easier to detect pathogens in resource-limited environments."

SeraParma™ COVID-19 IgM rapid test has high detection sensitivity, which can provide rapid detection of early COVID-19 infection. This SeraParma™ COVID-19 IgM rapid test can detect whether there are IgM antibodies produced in the early stage of infection (within 7 days of symptoms onset) with one drop of the specimen (serumfingertip blood) in 15 minutes by naked eyes compared with LFIA antibody rapid test. It is worth noting that the SeraParma™ COVID-19 IgM rapid test can accurately detect the patients with positive infection within 7 days of the onset of symptoms compared with LFIA.

We provide antibody-based solutions to human diseases with short development course at low cost, are based on the phage-displayed GH (Generic Human) synthetic antibody libraries designedconstructed with enabling approaches, leading to the throughput capacities to uplift the innovativenessproductivity in developing antibody therapeuticsdiagnostics. In conjunction with the core technologies, antibody bioinformatics capable of extracting knowledge from big data of human antibody repertoires is used to elucidate human antibody responsesto assist antibody library design.

Effectively inducing cytotoxic T cell expansion has been a critical challenge in vaccine development. To address this challenge, an entirely biodegradable polymeric nanoshell was invented to couple antigensadjuvants for safepotent immune potentiation. The invention has been adopted for precision anticancer vaccine, broadly reactive influenza vaccine,an effective vaccine MERS-CoV.